Strategic transactions and agreements - Ayala Pharmaceuticals - Fair value of assets acquired and liabilities (Details) - USD ($) $ in Thousands	May 25, 2024	Mar. 25, 2024	Sep. 30, 2025	Dec. 31, 2024
Assets acquired:
Other long-term assets			$ 4,555	$ 4,411
Total assets			299,377	240,241
Liabilities assumed:
Total liabilities			$ 35,458	$ 59,076
Ayala Asset Purchase Agreement
Asset acquisitions
Common stock issued		$ 50,645
Upfront consideration paid to Ayala	$ 20,000	20,039
Transaction costs		657
Consideration paid		71,341
Assets acquired:
In-process research and development		73,382
Other long-term assets		2,480
Total assets		75,862
Liabilities assumed:
Accrued expenses		4,521
Total liabilities		4,521
Net assets acquired		$ 71,341